Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds, UK.
Mod Rheumatol. 2010 Aug;20(4):325-30. doi: 10.1007/s10165-010-0277-7. Epub 2010 Mar 2.
Treatment outcomes in rheumatoid arthritis (RA) have improved considerably with the use of biological therapies. Since the discovery of the role of tumor necrosis factor (TNF) alpha in the pathogenesis of the disease, three TNF inhibitors, infliximab, etanercept and adalimumab, have become widely used for the treatment of RA. More recently, two newer TNF inhibitors-certolizumab pegol and golimumab-have become available, increasing the armamentarium of therapy. With improved therapies, treatment strategies have also changed, with the aims now being to achieve and maintain remission. This article addresses some of these aspects of treating RA, reviewing the studies on these two newer TNF inhibitors, certolizumab pegol and golimumab, and those addressing the induction of remission or low disease activity with TNF inhibitors and maintenance with less intensive treatment.
在使用生物疗法的情况下，类风湿关节炎（RA）的治疗效果得到了极大的改善。自肿瘤坏死因子（TNF）α在疾病发病机制中的作用被发现以来，三种 TNF 抑制剂——英夫利昔单抗、依那西普和阿达木单抗已被广泛用于 RA 的治疗。最近，两种新型 TNF 抑制剂——培塞利珠单抗和戈利木单抗也已上市，增加了治疗方法。随着治疗方法的改进，治疗策略也发生了变化，目前的目标是实现并维持缓解。本文将探讨这些治疗 RA 的方面，回顾这两种新型 TNF 抑制剂——培塞利珠单抗和戈利木单抗的研究，以及探讨使用 TNF 抑制剂诱导缓解或低疾病活动度以及使用较少强化治疗进行维持的研究。
